Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06395467 · ClinicalTrials.gov registry record · NA

Integrated Treatment for Enhancing Growth in Recovery During Adolescence

A NA study of Alcohol Use Disorder and Cannabis Use Disorder, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
294
Enrollment target
2
Study locations

NCT06395467 is a NA study of Alcohol Use Disorder and Cannabis Use Disorder that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 294 participants, below the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (10% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06395467, a NA study of Alcohol Use Disorder and Cannabis Use Disorder, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
294 participants
Enrollment target
2
Study locations

Study Summary

This is a Phase II parallel group randomized controlled trial with 294 adolescents (age: 14-21 years) with alcohol and other drug \[AOD\] use disorder (hereafter substance use disorder), that compares two different active psychosocial interventions designed to address adolescent substance use disorder. Participants are recruited from our clinical settings and the community at two sites: one in the metro Boston, Massachusetts (MA) area and the other in the metro Farmington, Connecticut (CT), area. Study aims and hypotheses are as follows: 1. To extend the evidence for the initial efficacy of Integrated Treatment for Enhancing Growth in Recovery During Adolescence (InTEGRA), which integrates 12-Step Facilitation (TSF) with Motivational Enhancement Therapy/Cognitive Behavioral Therapy (MET/CBT) relative to gold standard MET/CBT alone (N = 294). It is hypothesized that youth assigned to InTEGRA will have greater 12-step participation during and following treatment, higher abstinence rates, and fewer substance-related negative consequences. 2. Investigate the personal recovery capital (PRC) and social recovery capital (SRC) mechanisms of behavior change through which InTEGRA may confer benefits dynamically over time (e.g., PRC: motivation, self-efficacy, coping; SRC: 12-step involvement; social network changes). 3. Investigate moderators of InTEGRA's effects on outcomes across one-year follow-up (e.g., effect of age, network support for AOD use; psychiatric severity; age composition of 12-step meetings on substance use and substance-related consequences). It is hypothesized that higher network support for AOD use, abstinence motivation, and greater AOD severity, will have a better response to InTEGRA. 4. Explore barriers and facilitators to InTEGRA adoption and implementation across providers and system administrators within the context of a type I hybrid effectiveness-implementation research design.

Interventions

  • BEHAVIORAL InTEGRA
  • BEHAVIORAL MET/CBT

Study Locations (2)

Connecticut

  • UConn Health - Farmington

Massachusetts

  • MGH Department of Psychiatry - Boston

Trial Details

FieldValue
Enrollment Target 294 participants
Start Date 2024-11-26
Est. Completion 2028-05-31
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT06395467

The ClinicalTrials.gov registry entry for NCT06395467 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (10% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which InTEGRA is the first listed.

NCT06395467 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Connecticut, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06395467 about?

NCT06395467 is a clinical study titled "Integrated Treatment for Enhancing Growth in Recovery During Adolescence". This is a Phase II parallel group randomized controlled trial with 294 adolescents (age: 14-21 years) with alcohol and other drug \[AOD\] use disorder (hereafter substance use disorder), that compares two different active psychosocial interventions designed to address adolescent substance use disord...

What is the current status of trial NCT06395467?

This trial is currently recruiting. It is a NA study. The enrollment target is 294 participants. The study started on 2024-11-26. Estimated completion is 2028-05-31.

What conditions does trial NCT06395467 study?

This clinical trial studies the following conditions: Alcohol Use Disorder, Cannabis Use Disorder.

What interventions are being tested in trial NCT06395467?

The interventions under investigation include: InTEGRA (BEHAVIORAL), MET/CBT (BEHAVIORAL).

Who is sponsoring clinical trial NCT06395467?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06395467 being conducted?

This trial has 2 study locations across Connecticut, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.